Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HK1 | P19367 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236008 | 0.95 | LMNA (0.39) | LMNAKMT2AGAAMEN1ALDH1A1 | |
| SCHEMBL5233862 | 0.84 | KDM4E (0.40) | LMNAGAAALDH1A1ELANEMAPT | |
| SCHEMBL5236533 | 0.82 | ALDH1A1 (0.41) | KMT2AGAAMEN1ALDH1A1HPGD | |
| SCHEMBL5233819 | 0.82 | PLK1 (0.41) | LMNAKMT2AMEN1ALDH1A1ELANE | |
| SCHEMBL5240061 | 0.82 | LMNA (0.37) | LMNAKMT2AGAAMEN1ALDH1A1 | |
| SCHEMBL6110656 | 0.82 | SMN1; SMN2 (0.50) | LMNAKMT2AALDH1A1ELANEMAPT | |
| SCHEMBL5239883 | 0.80 | PTGDR2 (0.40) | LMNAGAAALDH1A1ELANEMAPT | |
| SCHEMBL5235815 | 0.79 | NMT1 (0.49) | LMNAKMT2AMEN1ALDH1A1DPP4 | |
| SCHEMBL5235308 | 0.78 | PLK1 (0.41) | LMNAKMT2AMEN1ALDH1A1ELANE | |
| SCHEMBL5238135 | 0.75 | NMT1 (0.47) | LMNAKMT2AMEN1ALDH1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| CN-1500080-A | Fused heterocyclic compounds | ����ҩƷ��ҵ��ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | LMNA 1764/4885KMT2A 452/4885GAA 310/4885 |
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | LMNA 4805/4885KMT2A 3453/4885GAA 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.